Multidrug and extensively drug-resistant tuberculosis from a general practice perspective.
作者： BM Yashodhara , Choo Beng Huat , Lakshmi Nagappa Naik , Shashikiran Umakanth , Manjunatha Hande
DOI: 10.2147/IDR.S10743
关键词:
摘要: Despite intensive efforts to eradicate the disease, tuberculosis continues be a major threat Indian society, with an estimated prevalence of 3.45 million cases in 2006. Emergence multidrug-resistant has complicated eradication attempts recent years. Incomplete and/inadequate treatment are main causes for development drug resistance. Directly observed therapy, short-course (DOTS) is World Health Organization (WHO) strategy worldwide tuberculosis, and our country achieved 100% coverage DOTS through Revised National Tuberculosis Control Program For patients WHO recommends DOTS-Plus strategy. Early detection prompt crucial avoid spread disease also because chances potentially incurable extensively drug-resistant these cases. This review discusses epidemiologic, diagnostic, therapeutic aspects outlines role primary care doctors management this dangerous disease.
elsevier.com
afpm.org.my参考文章(38)
Sharma Sk, Mohan A, Scientific basis of Directly Observed Treatment Short-course (DOTS). Journal of the Indian Medical Association. ,vol. 101, pp. 157- ,(2003)
Rajendra Prasad, None, Revised National Tuberculosis Control Programme: current scenario. Journal of the Indian Medical Association. ,vol. 107, pp. 725- 727 ,(2009)
K. Park, Park's Textbook of Preventive and Social Medicine ,(2015)
Vinay K. Sharma, Karim Djekidel, Marian Haber, Alan D. Haber, INCIDENCE OF POLARIZING FOREIGN BODIES IN LUNG BIOPSIES OF PATIENTS WITH PULMONARY SARCOIDOSIS Chest. ,vol. 130, pp. 143S- 272 ,(2006) , 10.1378/CHEST.130.1.261
L Rigouts, I Bastian, F Portaels, A Van Deun, Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bulletin of The World Health Organization. ,vol. 78, pp. 238- 251 ,(2000) , 10.1590/S0042-96862000000200014
P. Brown, Drug resistant tuberculosis can be controlled, says WHO BMJ. ,vol. 320, pp. 821- 821 ,(2000) , 10.1136/BMJ.320.7238.821
Payam Tabarsi, Ehsan Chitsaz, Parvaneh Baghaei, Masoud Shamaei, Parisa Farnia, Majid Marjani, Mehdi Kazempour, Majid Amiri, Davood Mansouri, Mohammad R Masjedi, Ali A Velayati, Jose A Caminero, None, Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Microbial Drug Resistance. ,vol. 16, pp. 81- 86 ,(2010) , 10.1089/MDR.2009.0073
M. Chaitanya, B. Babajan, C. M. Anuradha, M. Naveen, C. Rajasekhar, P. Madhusudana, Chitta Suresh Kumar, Exploring the molecular basis for selective binding of Mycobacterium tuberculosis Asp kinase toward its natural substrates and feedback inhibitors: A docking and molecular dynamics study Journal of Molecular Modeling. ,vol. 16, pp. 1357- 1367 ,(2010) , 10.1007/S00894-010-0653-4
Leonard Amaral, Martin J. Boeree, Stephen H. Gillespie, Zarir F. Udwadia, Dick van Soolingen, Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! International Journal of Antimicrobial Agents. ,vol. 35, pp. 524- 526 ,(2010) , 10.1016/J.IJANTIMICAG.2009.12.019
Leonard Amaral, Joseph Molnar, Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use". Recent Patents on Anti-infective Drug Discovery. ,vol. 5, pp. 109- 114 ,(2010) , 10.2174/157489110791233540